^
    1m
    HFB-301001-01: A Study of HFB301001 in Adult Patients With Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=31, Terminated, HiFiBiO Therapeutics | N=84 --> 31 | Active, not recruiting --> Terminated; The decision to discontinue the trial was made as part of a strategic review of the Sponsor's global development portfolio. It is not related to any safety concerns, efficacy findings, recruitment difficulties, or issues with trial conduct.
    Enrollment change • Trial termination
    |
    BRAF (B-raf proto-oncogene)
    |
    BRAF V600
    |
    HFB301001
    7ms
    HFB-301001-01: A Study of HFB301001 in Adult Patients With Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=84, Active, not recruiting, HiFiBiO Therapeutics | Trial completion date: Jan 2025 --> Aug 2026 | Trial primary completion date: Jan 2025 --> May 2024
    Trial completion date • Trial primary completion date
    |
    BRAF (B-raf proto-oncogene)
    |
    BRAF V600
    |
    HFB301001
    over1year
    HFB-301001-01: A Study of HFB301001 in Adult Patients With Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=84, Active, not recruiting, HiFiBiO Therapeutics | Recruiting --> Active, not recruiting | Trial completion date: Jan 2024 --> Jan 2025 | Trial primary completion date: Jan 2024 --> Jan 2025
    Enrollment closed • Trial completion date • Trial primary completion date • Metastases
    |
    BRAF (B-raf proto-oncogene)
    |
    BRAF V600
    |
    HFB301001